The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology

The majority of women diagnosed with breast cancer will experience some form of drug-related toxicity and subsequent impairments in Health-related Quality of Life (HRQoL). Despite this, HRQoL is assessed inconsistently and there is no validated method to integrate HRQoL data into the assessment of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Basu, A., Philip, E. J., Dewitt, B., Hanmer, J., Chattopadhyay, A., Yau, C., Melisko, M. E., Esserman, L. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560724/
https://www.ncbi.nlm.nih.gov/pubmed/33083531
http://dx.doi.org/10.1038/s41523-020-00193-6
_version_ 1783595141336924160
author Basu, A.
Philip, E. J.
Dewitt, B.
Hanmer, J.
Chattopadhyay, A.
Yau, C.
Melisko, M. E.
Esserman, L. J.
author_facet Basu, A.
Philip, E. J.
Dewitt, B.
Hanmer, J.
Chattopadhyay, A.
Yau, C.
Melisko, M. E.
Esserman, L. J.
author_sort Basu, A.
collection PubMed
description The majority of women diagnosed with breast cancer will experience some form of drug-related toxicity and subsequent impairments in Health-related Quality of Life (HRQoL). Despite this, HRQoL is assessed inconsistently and there is no validated method to integrate HRQoL data into the assessment of therapeutic agents. This proof of concept study utilizes data from the neoadjuvant I-SPY 2 clinical trial to describe the development of the Quality of Life Index (QoLI) measure. The QoLI represents a single composite score that incorporates validated longitudinal measures of clinical efficacy and QoL and one that permits a more comprehensive, direct comparison of individual therapeutic agents. Preliminary data suggest the QoLI is able to distinguish between agents based on their efficacy and toxicity; with further validation, the QoLI has the potential to provide more patient-centered evaluations in clinical trials and help guide treatment decision making in breast cancer and other oncologic diseases.
format Online
Article
Text
id pubmed-7560724
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75607242020-10-19 The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology Basu, A. Philip, E. J. Dewitt, B. Hanmer, J. Chattopadhyay, A. Yau, C. Melisko, M. E. Esserman, L. J. NPJ Breast Cancer Brief Communication The majority of women diagnosed with breast cancer will experience some form of drug-related toxicity and subsequent impairments in Health-related Quality of Life (HRQoL). Despite this, HRQoL is assessed inconsistently and there is no validated method to integrate HRQoL data into the assessment of therapeutic agents. This proof of concept study utilizes data from the neoadjuvant I-SPY 2 clinical trial to describe the development of the Quality of Life Index (QoLI) measure. The QoLI represents a single composite score that incorporates validated longitudinal measures of clinical efficacy and QoL and one that permits a more comprehensive, direct comparison of individual therapeutic agents. Preliminary data suggest the QoLI is able to distinguish between agents based on their efficacy and toxicity; with further validation, the QoLI has the potential to provide more patient-centered evaluations in clinical trials and help guide treatment decision making in breast cancer and other oncologic diseases. Nature Publishing Group UK 2020-10-14 /pmc/articles/PMC7560724/ /pubmed/33083531 http://dx.doi.org/10.1038/s41523-020-00193-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Brief Communication
Basu, A.
Philip, E. J.
Dewitt, B.
Hanmer, J.
Chattopadhyay, A.
Yau, C.
Melisko, M. E.
Esserman, L. J.
The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology
title The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology
title_full The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology
title_fullStr The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology
title_full_unstemmed The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology
title_short The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology
title_sort quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560724/
https://www.ncbi.nlm.nih.gov/pubmed/33083531
http://dx.doi.org/10.1038/s41523-020-00193-6
work_keys_str_mv AT basua thequalityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT philipej thequalityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT dewittb thequalityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT hanmerj thequalityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT chattopadhyaya thequalityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT yauc thequalityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT meliskome thequalityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT essermanlj thequalityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT basua qualityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT philipej qualityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT dewittb qualityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT hanmerj qualityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT chattopadhyaya qualityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT yauc qualityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT meliskome qualityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology
AT essermanlj qualityoflifeindexapilotstudyintegratingtreatmentefficacyandqualityoflifeinoncology

Ejemplares similares